Gener8 , a product realization company in the life sciences and medical device markets, has named David Brakenwagen CEO as it announces changes within its executive leadership. The company’s founder, David Klein, will continue full time as a key executive and will focus on developing deeper relationships and solving key technical challenges with core customers. Having held senior executive positions within operations, sales and marketing, and engineering organizations for more than 20 years, Brakenwagen brings deep industry experience to the role.
“We are very excited to add David Brakenwagen to the Gener8 executive team,” says Dave Finley, managing partner at Sverica Capital Management. “David brings a complimentary skill set to our existing leadership team, which will continue to fuel Gener8’s platform of differentiated and value add services to our key end markets.”
Gener8, which has locations in Sunnyvale, CA, and Boston, MA, offers full product life cycle engineering and manufacturing for highly complex medical instruments and products.
“Gener8 is moving into the next phase of company growth, adding capacity and services to better serve the life sciences and medical device communities,” says Brakenwagen. “These changes are driving the need for expanding our leadership team brings a unique and complimentary perspective to the next phases of our strategic vision. As Gener8 moves forward into the next phase of opportunities to create value, I look forward to expanding the tremendous foundation Gener8 has in the marketplace.”